Stacey Cohen, MD, reviews the initial results from the phase 2 COBRA study focused on ctDNA as a predictive biomarker in adjuvant chemotherapy for patients with stage II colon cancer.
FDA Accepts NDA Resubmission of Rivoceranib/Camrelizumab in uHCC
The resubmission included an analysis of the phase 3 CARES-310 study, which reported favorable overall survival with the combination therapy in uHCC.
Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.
Neoadjuvant Sotigalimab Proves Efficacious in Rectal Cancer
Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.
Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited Institutions
Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.
Fruquintinib Approved in Japan for Unresectable Advanced or Recurrent CRC
The approval is based on results from the global phase 3 FRESCO-2 trial, which demonstrated improvement in OS in patients with refractory metastatic colorectal cancer.
Non-Operative Management Does Not Compromise DRFS in pMMR Rectal Cancer
NO-CUT trial data show that DRFS was maintained when non-operative management was used in patients with pMMR locally advanced rectal cancer.